CRISPR Therapeutics AG (CRSP) Form 8-K — Oct 19, 2026

$CRSPForm 8-KItems 5.02, 9.01Filed Oct 19, 2026, 4:11 PM ET0001193125-26-425243Original filing

CRISPR Therapeutics promoted Andrew J. Silver, previously SVP of Finance, to Chief Financial Officer effective October 19, 2026, replacing Raju Prasad who resigned to pursue external opportunities. Silver has been with the company since October 2018 and spent over ten years at Ernst & Young before joining. He receives a $515,000 base salary, a 45% target bonus, and a one-time grant of 25,000 RSUs vesting in two years.

Key figures

Rsu award: 25000
Cfo salary usd: 515000
Target bonus pct: 45
Notice period months: 6
Cic notice period months: 12

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.